Oncotelic Therapeutics, Inc.
OTLC
$0.0569
-$0.0018-3.07%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 81.82% | -1,475.07% | 48.67% | 44.47% | -738.33% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -66.22% | -76.98% | 69.21% | -87.41% | 219.90% |
| Total Other Non-Cash Items | -87.82% | 3,380.54% | -576.68% | -95.36% | 245.16% |
| Change in Net Operating Assets | -3.19% | 628.40% | -120.25% | 133.88% | -303.68% |
| Cash from Operations | 27.44% | 45.30% | -13.14% | 37.90% | -49.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -81.36% | 51.72% | -42.00% | -16.67% | -28.57% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 50.00% |
| Cash from Financing | -81.36% | 51.72% | -42.00% | -9.09% | -17.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -181.90% | 165.75% | -727.96% | 119.06% | -213.23% |